|
Wed, 03/25/2020 - 07:55 |
ENHERTU Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer |
Daiichi Sankyo |
|
Wed, 01/08/2020 - 21:11 |
Blueprint Medicines Announces FDA Approval of AYVAKIT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor |
Blueprint Medicines |
|
Thu, 08/15/2019 - 18:45 |
FDA Approves Genentechs Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors |
Genentech |
|
Mon, 07/29/2019 - 08:00 |
Kaplan USMLE Step 1 prep: Which drug to blame for womans symptoms? |
AMA |
|
Tue, 03/05/2019 - 08:40 |
SPRAVATO uses the first new mechanism of action in decades to treat major depressive disorder 1,2,3 |
Johnson and Johnson |
|
Thu, 02/28/2019 - 09:42 |
FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers |
Genentech |
|
Mon, 01/07/2019 - 07:04 |
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain |
AcelRx Pharmace... |
|
Fri, 12/21/2018 - 04:11 |
Novartis receives European Commission (EC) approval for expanded indication for Kisqali (ribociclib) |
Novartis |
|
Thu, 12/20/2018 - 13:22 |
Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML |
Daiichi Sankyo |
|
Thu, 12/20/2018 - 03:42 |
LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Wed, 12/19/2018 - 04:35 |
LYNPARZA (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Mon, 12/17/2018 - 12:54 |
Teva Announces Positive Topline Phase IIIb Results with Fremanezumab in Adults with Migraine Who Did Not Respond to Multiple Classes of Preventive Treatments |
Teva Pharmaceutical |
|
Mon, 12/17/2018 - 10:57 |
PRIME designation granted by European Medicines Agency for Roches risdiplam for treatment of spinal muscular atrophy (SMA) |
Rocheusa |
|
Thu, 12/13/2018 - 13:50 |
Whooping cough makes an appearance in Indiana |
Purdue |
|
Thu, 12/13/2018 - 10:44 |
Health Canada Grants Market Authorization for ORKAMBI (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease |
Vertex |
|
Tue, 12/11/2018 - 12:43 |
The food poisoning find that could save lives. |
ANUniversity |
|
Mon, 12/10/2018 - 07:06 |
Astellas Launches XOSPATA (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation |
Astellas |
|
Sat, 12/08/2018 - 01:30 |
Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease |
Novartis |
|
Thu, 12/06/2018 - 10:18 |
Shellfish biotoxin alert for the Bay of Islands in Northland |
MPI NZ |
|
Wed, 12/05/2018 - 21:55 |
FDA Approves Genentechs Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer |
Genentech |
|
Wed, 12/05/2018 - 20:04 |
International Medical Corps in Yemen |
IMC |
|
Tue, 12/04/2018 - 23:19 |
Genentechs Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment |
Genentech |
|
Tue, 12/04/2018 - 08:10 |
(TOKYO: 4519) announced that the primary analysis of the phase III HAVEN 2 study (NCT02795767), evaluating hemophilia A treatment HEMLIBRA |
Chugai |
|
Mon, 12/03/2018 - 20:55 |
FDA Grants Priority Review to Genentechs Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer |
Genentech |
|
Mon, 12/03/2018 - 16:34 |
Comprehensive Positive Phase 3 Data for Alexions ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood |
Alexion |
